Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 35, 2021 - Issue 22
204
Views
6
CrossRef citations to date
0
Altmetric
Short Communications

Anticancer activity of oleiferoside B involving autophagy and apoptosis through increasing ROS release in MCF-7 cells and SMMC-7721 cells

, , , , , , & show all
Pages 4865-4869 | Received 07 Oct 2019, Accepted 26 Feb 2020, Published online: 18 Mar 2020
 

Abstract

Oleiferoside B is a triterpenoid monomer compound, mainly isolated from roots of Camellia oleifera Abel, the underlying mechanism of its antitumour is not clear. In the present study, oleiferoside B potently inhibited SMMC-7721 and MCF-7 cells proliferation and cause cells apoptosis. In addition, it activated an autophagy-mediated cell death pathway, as indicated by the accumulated the ratio of LC3- II/LC3- I and inhibited apoptosis protein expression after pre-treatment with autophagy inhibitors 3-MA. Further studies showed that oleiferoside B-induced apoptosis and autophagy was attributed to ROS release. In vivo oleiferoside B (1.0, 0.5 mg/kg) effectively suppressed tumour growth. In conclusion, our finding reveals a novel mechanism of action of oleiferoside B in cancer cells via induction of apoptosis and autophagy through ROS generation. Therefore, our results provided new insight into the mechanism of the antitumour effect of oleiferoside B as a prospective therapeutic drug in the tumour.

Graphical Abstract

Disclosure statement

No potential conflict of interest was reported by the authors.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.